CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers

PHASE3CompletedINTERVENTIONAL

Enrollment

230

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

April 30, 2011

Conditions

CancerNeoplasmsCarcinomaMalignant Ascites

Interventions

DRUG

Catumaxomab

"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"

DRUG

Prednisolone

25 mg premedication

Trial Locations (4)

Study Site, Several

Study site, Several

Study Site, Several